News Breaks |
|
|
| March 8, 2013 |
| 08:04 EDT |  | STJ | St. Jude Medical announces first implant in trial evaluating AMPLATZER plug
St. Jude Medical announced the first patient implant in a new pivotal trial evaluating the company’s AMPLATZER Cardiac Plug for the prevention of stroke. The AMPLATZER Cardiac Plug Clinical Trial is designed to determine if the ACP device is safe and effective in preventing thrombus (blood clots) from migrating out of the left atrial appendage in patients with non-valvular atrial fibrillation who have a high risk for stroke. The ACP Trial is a prospective, randomized, multi-center clinical study with an adaptive trial design that will enroll no fewer than 400 and no more than 3,000 patients at up to 90 sites in the U.S. and Canada. The trial compares the safety and efficacy of the ACP device to traditional medical treatment using long-term, blood-thinning medication. |
|
|
News For STJ From The Last 14 Days Check below for free stories on STJ the last two weeks. |
|
|
| May 23, 2013 |
| 05:44 EDT | | STJ | St. Jude Medical study of EnligHTN shows sustained blood pressure reduction
St. Jude Medical announced that the company's EnligHTN Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after one year. Patients enrolled in the EnligHTN I trial had an average blood pressure of 176 / 96 mmHg and patients were drug-resistant, meaning their blood pressure could not be controlled through medication. At one year, patients treated with the EnligHTN Renal Denervation System experienced an average systolic blood pressure reduction of 27 mmHg points when measured in an office setting. |
|
| May 20, 2013 |
| 11:12 EDT | | STJ | St. Jude Medical to evaluate defibrilator lead related to reported death
 Subscribe for More Information |
|
| May 16, 2013 |
| 08:05 EDT | | STJ | St. Jude Medical's 3-D vessel reconstruction system approved in Europe
St. Jude Medical announced CE Mark approval of its Ilumien Optis PCI Optimization System, a new technology designed to provide physicians with a comprehensive disease assessment tool for treating patients with coronary artery disease. St. Jude Medical is the only company to provide these tools together in an integrated platform. |
|
| May 14, 2013 |
| 08:09 EDT | | STJ | St. Jude Medical announces first patient enrolled in EnligHTN III study
Subscribe for More Information |
|
| May 9, 2013 |
| 14:01 EDT | | STJ | St. Jude says analysis demonstrates safety, reliability of Optim-insulated leads
Subscribe for More Information |
|
| 09:27 EDT |  | STJ | Leerink's medical devices analyst holds a conference call
Subscribe for More Information |
|
|
|
|
|
